Your AI-Trained Oncology Knowledge Connection!
The Association of Community Cancer Centers will honor the recipients of 2018 ACCC Innovator Awards at the ACCC 35th National Oncology Conference, October 17-19 in Phoenix, Arizona, where this year’s honorees will share strategies and lessons learned from their own experience to enable others to model and scale similar initiatives.
The European Commission has approved CPX-351 (Vyxeos), a fixed-combination of daunorubicin and cytarabine, for adult patients with newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.
The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.
The FDA has approved ibrutinib in combination with rituximab for the treatment of patients with Waldenström macroglobulinemia.
Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.
A. David McCollum, MD, discusses the need for greater use of molecular profiling, the importance of tumor sidedness when selecting a treatment regimen, and the value of maintenance therapy in patients with metastatic disease.
Jonathon B. Cohen, MD, discusses the potential benefit of offering deferred therapy to asymptomatic patients with mantle cell lymphoma.
Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.
Ryan D. Gentzler, MD, highlights how chemotherapy remains a critical component of the metastatic non–small cell lung cancer treatment paradigm.
Noopur Raje, MD, discusses the latest treatment advances in multiple myeloma.
Judith Trotman, MBChB, FRACP, FRCPA, discusses zanubrutinib’s effect on patient quality of life and how the BTK inhibitor can be used to extend survival for younger patients with WM.
Gary H. Lyman, MD, FASCO, interprets the available information on biosimilars as it relates to the clinical oncology community.
The European Commission has approved lenvatinib (Lenvima) as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma.
Combining Alpelisib (BYL719) with fulvestrant improved progression-free survival versus fulvestrant alone in postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor, meeting the primary endpoint of the phase III SOLAR-1 trial.
The FDA has granted a priority review to a supplemental biologics license application for elotuzumab for use in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor.
Michael J. Overman, MD, discusses the current state of immunotherapy in patients with CRC and how to optimally manage immune-related adverse events.
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved osimertinib for the frontline treatment of patients with inoperable or recurrent EGFR-positive non–small cell lung cancer.
The US Preventive Services Task Force issued new guidelines recommending that women aged 30 to 65 years at average risk for cervical cancer can choose to receive a Pap smear alone every 3 years or screening with the high-risk human papillomavirus test alone or cotesting every 5 years.
Francisco J. Esteva, MD, PhD, discusses the journey of CT-P6 and its promise as a potential biosimilar for trastuzumab in the United States.
Lee Schwartzberg, MD, discusses a retrospective analysis of patients with nonmyeloid cancer who received a filgrastim biosimilar versus the filgrastim biologic and explains how biosimilars have the potential to transform the field of oncology beyond the scope of supportive care.
The China National Drug Administration has approved alectinib for the treatment of patients with ALK-positive, advanced non–small cell lung cancer.
Edward B. Garon, MD, discusseds early findings with pegilodecakin in non–small cell lung cancer.
Nikhil C. Munshi, MD, discusses the current treatment landscape of myeloma and potential next steps to further advancing care.
Scott Paulson, MD, discusses recent updates in the treatment of patients with neuroendocrine tumors.
Leonid Shunyakov, MD, discusses the impact genomics has on personalized therapy and the roster of available therapies that continues to grow as a result of identifiable genomic drivers.
The FDA has granted a full approval to frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.
Ursula A. Matulonis, MD, highlights the activity and tolerability of niraparib and discusses other recent data in ovarian cancer.
Hackensack Meridian Health, New Jersey’s largest and most comprehensive healthcare network, is proud to announce the opening of the Institute for Multiple Myeloma which will support groundbreaking research to enhance treatment of this rare cancer.
The FDA has approved single-agent nivolumab for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.
The FDA has approved lenvatinib as a first-line treatment for patients with unresectable hepatocellular carcinoma.